Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE: Rebif New Formulation in RRMS
NCT00441103Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2006
- Primary completion
- Nov 2008
- Modality
- Cytokines & Interferons
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Rebif Group with Placebo/Rebif Group (2 arms). Primary endpoint: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at 16 weeks. Started Dec 2006; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00441103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441103.